
Faculty Scholarship

2022

Help Was Not on the Way: Intellectual Property Liability Relief in a Pandemic Era

Kim Vu-Dinh

Mitchell Hamline School of Law, kim.vudinh@mitchellhamline.edu

Follow this and additional works at: <https://open.mitchellhamline.edu/facsch>



Part of the [Intellectual Property Law Commons](#)

Publication Information

11 *Arkansas Journal of Social Change and Public Service* 30 (2022)

Repository Citation

Vu-Dinh, Kim, "Help Was Not on the Way: Intellectual Property Liability Relief in a Pandemic Era" (2022).
Faculty Scholarship. 571.

<https://open.mitchellhamline.edu/facsch/571>

This Article is brought to you for free and open access by Mitchell Hamline Open Access. It has been accepted for inclusion in Faculty Scholarship by an authorized administrator of Mitchell Hamline Open Access. For more information, please contact sean.felhofer@mitchellhamline.edu.

Help Was Not on the Way: Intellectual Property Liability Relief in a Pandemic Era

Abstract

On January 21, 2020, the United States recorded its first case of COVID-19. By April of that same year, numerous hospitals across the nation had exhausted entire reserves of personal protective equipment (PPE), with looming uncertainty as to when they would be replenished. As infection numbers increased exponentially, global demand for some types of PPE increased by 1000%.

Volunteers across the nation assembled teams of makers—some professionals, but also scores of amateurs—to craft the critical equipment needed to slow down the onslaught of the pandemic. From creating cloth masks to ventilator pistons, nonprofits and everyday citizens were able to partially alleviate a need that neither the private sector nor the government could address adequately.

Extensive potential intellectual property (IP) infringement liabilities exist for these well-meaning volunteers. For example, using open-source, freely-dispersed blueprints could in fact be an unwitting violation of an obscure, pre-existing invention whose patent is buried deep within the unwieldy database of the U.S. Patent and Trademark Office. Moreover, the threat of liability extends beyond micromanufacturers to include also distributors, distribution facilitators, and those who circulate patented plans or copyrighted ideas.

Currently, no defenses to such infringement exist, dissuading would-be heroes from assisting during a great time of need. As one recent commentary notes, “[t]he threat of infringement also dampens the ability to innovate under conditions of emergency, intensifying the tension between the protection of IP and the protection of human lives.” Defendants could, however, look to other legal doctrines. In analogizing intellectual property to the common law, one might argue for a Good Samaritan doctrine or to the necessity defense to trespass from tort law. As in landlord-tenant law, to the extent that rents for real property have been deferred during the time of the pandemic, perhaps certain instances of intangible property “rent seeking” by the owners of patents and copyrights might be justifiably put on hold as well. Defendants in IP lawsuits could also look to creative applications of existing exceptions in patent law such as march-in rights and the Defense Protection Act.

Using this PPE and medical device production dilemma as a case study, this Article will consider the logistical and legal obstacles to accommodating public interest uses of intellectual property. My analysis will recommend a procedure that would limit or defer liability and provide appropriate remedies, and also would incentivize crucial and well-meaning acts in times of pandemic.

Keywords

Personal protective equipment, Pandemics, Public interest, Intellectual property, Infringement

Disciplines

Intellectual Property Law

HELP WAS NOT ON THE WAY: INTELLECTUAL PROPERTY LIABILITY RELIEF IN A PANDEMIC ERA

*Kim Vu-Dinh**

I. INTRODUCTION

On January 21, 2020, the United States recorded its first case of COVID-19.¹ By April of that same year, numerous hospitals across the nation had exhausted entire reserves of personal protective equipment (PPE), with looming uncertainty as to when they would be replenished.² As infection numbers increased exponentially, global demand for some types of PPE increased by 1000%.³

Volunteers across the nation assembled teams of makers—some professionals, but also scores of amateurs—to craft the critical equipment needed to slow down the onslaught of the pandemic. From creating cloth masks to ventilator pistons, nonprofits and everyday citizens were able to partially alleviate a need that neither the private sector nor the government could address adequately.⁴

Extensive potential intellectual property (IP) infringement liabilities exist for these well-meaning volunteers. For example, using open-source, freely-dispersed blueprints could in fact be an unwitting violation of an obscure, pre-existing invention whose patent is buried deep within the unwieldy database of the U.S. Patent and Trademark Office. Moreover, the threat of liability extends beyond micromanufacturers to include also distributors, distribution facilitators, and those who circulate patented plans or copyrighted ideas.

Currently, no defenses to such infringement exist, dissuading would-be heroes from assisting during a great time of need. As one recent commentary

* Assistant Professor of Law, Director of the Business Innovations Legal Clinic, Bowen School of Law, University of Arkansas at Little Rock. This Article was completed with the assistance of a grant from the University of Arkansas at Little Rock William H. Bowen School of Law.

¹ AJMC Staff, The Center for Biosimilar Blog, *A Timeline of COVID-19 Developments in 2020* (January 21, 2021), <https://www.ajmc.com/view/a-timeline-of-covid19-developments-in-2020>.

² Ken Budd, *Where is all the PPE?* (Mar 27, 2020), <https://www.aamc.org/news-insights/where-all-ppe>.

³ Tahla Burki, *Global shortage of personal protective equipment*, *Lancet Infect Dis.*, (July 2020) 20(7): 785–86.

⁴ *See infra*, sections II (c).

notes, “[t]he threat of infringement also dampens the ability to innovate under conditions of emergency, intensifying the tension between the protection of IP and the protection of human lives.”⁵ Defendants could, however, look to other legal doctrines. In analogizing intellectual property to the common law,⁶ one might argue for a Good Samaritan doctrine or to the necessity defense to trespass from tort law. As in landlord-tenant law, to the extent that rents for real property have been deferred during the time of the pandemic, perhaps certain instances of intangible property “rent seeking” by the owners of patents and copyrights might be justifiably put on hold as well.⁷ Defendants in IP lawsuits could also look to creative applications of existing exceptions in patent law such as march-in rights and the Defense Protection Act.

Using this PPE and medical device production dilemma as a case study, this Article will consider the logistical and legal obstacles to accommodating public interest uses of intellectual property. My analysis will recommend a procedure that would limit or defer liability and provide appropriate remedies, and also would incentivize crucial and well-meaning acts in times of pandemic.

This Article will proceed in multiple parts. Part II provides a case study centering on the coronavirus pandemic and the PPE problem, illustrating that volunteers would benefit from relief from the threat of intellectual property infringement to incentivize their public interest efforts. Part III(A) outlines the growing trend of intellectual property jurisprudence in strengthening intellectual property rights to the extent some consider them moral rights as well as a critique of this trend. Part III(B) details the need for exceptions to intellectual property liability, focusing on other patentable subject matter valuable to the public domain during times of crisis. Part III(C) focuses on

⁵ Yaniv Heled, Ana Santos Rutschman & Liza Vertinsky, *The Need for the Tort Law Necessity Defense in Intellectual Property Law*, U. CHI. LEGAL F. (forthcoming) (manuscript at 1), https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3642833&download=yes.

⁶ This analogy is discussed at length in the context of IP takings. See Dustin Marlan, *Trademark Takings: Trademarks as Constitutional Property Under the Fifth Amendment Takings Clause*, 15 U. PA. J. CONST. L. 1581, 1616-18 (2013) (drawing on patent law precedent and finding that trademarks constitute, for better or worse, a similar form of property as real property). See also Irina D. Manta, *Keeping IP Real*, 57 HOUS. L. REV. 349, 349 (2019) (analyzing the relationship between IP and tangible property).

⁷ See Brian L. Frye, *Literary Landlords in Plaguetime*, 10 N.Y. U. J. INTELL.

copyright (though much is applicable in the realm of patent also) and deals conceptually with analogies to the common law—property and tort law—where safety valves to liability exist in the form of Good Samaritan laws, the public necessity defense to trespass, and moratoriums to eviction in the context of landlord-tenant law during COVID-19. Part III(D) explores other common law analogies available as a model for potential legislation.

II. THE THREAT OF IP LIABILITY IN A PANDEMIC ERA

Very few countries were prepared for such a quickly-evolving pandemic.⁸ The U.S. went from fifteen cases on February 15, 2020 to 718,000 cases by May 15, 2020.⁹ By July 26 of that year, the U.S. reported a staggering 4.1 million cases total and 145,000 deaths.¹⁰ Vaccines have rolled out in the U.S., the UK, and Israel the most efficaciously, but because of wealth and distribution issues, countries of the European Union, let alone those in South America and Africa, are projecting widespread vaccination only from late 2021 to early 2023, respectively.¹¹ Some commentators argue that due to our globalist economy, an ineffective rollout of vaccines internationally leave us all vulnerable to a never-ending pandemic.¹² In short, while there has been a

⁸ See, e.g., *Two first coronavirus cases confirmed in Italy: prime minister*, REUTERS (Jan 30, 2020), <https://www.reuters.com/article/us-china-health-italy/two-first-coronavirus-cases-confirmed-in-italy-prime-minister-idUSKBN1ZT31H>; *Ciro Indolfi and Carmen Spaccarotella, The Outbreak of COVID-19 in Italy - Fighting the Pandemic*, J AM COLL CARDIOL CASE REP. 2020 Jul, 2 (9), 1414-1418; *Barbie Latza Nadeau and Livia Borghese, Europe's biggest countries are seeing Covid surges -- but not this one*, CNN (August 10, 2020, 3:06AM), <https://www.cnn.com/2020/08/09/europe/italy-coronavirus-return-normal-intl/index.html>; *Italy Coronavirus Map and Case Count*, NY TIMES (As of 7/26/20), <https://www.nytimes.com/interactive/2020/world/europe/italy-coronavirus-cases.html>; *Brazil Coronavirus Map and Case Count*, NY TIMES (As of 7/26/20), <https://www.nytimes.com/interactive/2020/world/americas/brazil-coronavirus-cases.html>. Also in July, President Bosonaro and his wife contracted the disease. See Alison Durkee, *Brazilian President Jair Bolsonaro Tests Positive For Covid-19*, FORBES (Jul 7, 2020).

⁹ *Id.*

¹⁰ *COVID Data Tracker*, CDC, <https://www.cdc.gov/covid-data-tracker/#cases> (last visited on July 26, 2020).

¹¹ Stephanie Hegarty, *Covid vaccine tracker: How's my country and the rest of the world doing?*, BBC NEWS (Feb. 21, 2021), <https://www.bbc.com/news/world-56025355>.

¹² See Katherine Gammon, *Why a failure to vaccinate the world will put us all at risk*, MIT Technology Review (Feb 13, 2021), <https://www.technologyreview.com/2021/02/13/1018259/why-a-failure-to->

return to semi-normalcy for those who have been vaccinated in the U.S., it is not clear whether or when the end is in sight for COVID-19.

A. Critical Shortages of PPE

Bombarded with a pandemic of this breadth and scale, hospitals all over the globe quickly extinguished their supplies of the most basic personal protective equipment (PPE) such as hospital gowns, face masks, and face shields, and started re-using them against CDC protocol.¹³ An immediate shortage of ventilator parts and hand sanitizer also became apparent.¹⁴ At the University of Washington in Seattle, an entire shipment of N95 masks was stolen off of its loading docks; at George Washington University Hospital in Washington DC, individuals walked into the hospital to steal massive quantities of supplies.¹⁵ Indeed, in response to a 2020 American Medical Association (AMA) survey, more than one-third of a sample of 3,500 physicians reported that acquiring PPE was “very” or “extremely” difficult.¹⁶ Smaller medical practices reported even greater difficulties—41% of doctors in practices of five or fewer members reported saying that PPE was “very” or “extremely” difficult to obtain.¹⁷ As physician Susan R. Bailey put it:

Nobody is immune to this. It doesn't matter who you are. If the president of the AMA is having a hard time finding PPE, that is a clear expression of how incredibly difficult it is for the entire physician population.¹⁸

As of Spring 2021, even with millions of Americans vaccinated against

vaccinate-the-world-will-put-us-all-at-risk/; Jaimy Lee, *Dr. Osterholm: Americans will be living with the coronavirus for decades*, MarketWatch (Aug. 1 2020, 10:59 AM), <https://www.marketwatch.com/story/osterholm-americans-will-be-living-with-the-coronavirus-for-decades-2020-07-30>.

¹³ Budd, *supra* note 2.

¹⁴ Health care institutions, from great to small, also had insufficient COVID-19 tests. See Planet Money, *How to Test a Country*, NPR, at 9:16 PM (March 18, 2020), <https://www.npr.org/transcripts/818072542>. However, because there is no known occurrence of test duplication by lay people and lay organizations, and hence, no known risk of unwitting IP infringement in test development, we do not address this issue in this article. The content of this article focuses on equipment and supplies that were easily produced by lay people

¹⁵ Budd, *supra* note 2.

¹⁶ Kevin B. O'Reilly, *Amid PPE shortage, AMA collaboration offers supplier for doctors*, AMA (Apr. 13, 2021), <https://www.ama-assn.org/delivering-care/public-health/amid-ppe-shortage-ama-collaboration-offers-supplier-doctors>.

¹⁷ *Id.*

¹⁸ *Id.*

COVID-19, many physicians in the U.S. continue to report access problems relating to PPE.¹⁹ Even among practices who can access PPE, costs remain a serious concern, with physicians spending on PPE rising above 57% in 2020.²⁰

B. Government Response

The response from the federal government failed to effectively remedy the PPE shortages. Federal agencies did not remove barriers to enable the private sector to act in a timely manner. For instance, the U.S. Center for Disease Control (CDC) was unable to produce its coronavirus tests at the scale needed and requested the FDA to grant waivers permitting private sector manufacturers to develop and reproduce tests of their own.²¹ Not until February 29, 2020 was such waiver given,²² over one month after the first confirmed case in U.S.²³

Similar patterns in response time were evident for medical device uses. Not until almost two months into the pandemic did the FDA issue emergency use authorizations (EUA) allowing hospitals and other healthcare providers to use certain devices that had not yet gone through FDA approval, or had received approval for other uses but not the ones needed to serve the COVID-19 patients.²⁴ The EUA was accompanied by a declaration limiting liability for manufacturers of such devices.²⁵ This declaration was reserved, however, only for certain diagnostic tests, decontamination systems, respirators, certain ventilator parts, and face shields; it did not address reproduction of gowns, gloves, or non-respirator face masks and the protection was primarily focused on PPE made by professional manufacturers of similar devices made in other countries with their own national standards. In short, the protections were limited to those companies and individuals who were already in the

¹⁹ *Id.*

²⁰ *Id.*

²¹ Budd, *supra* note 2.

²² *Coronavirus (COVID-19) Update: FDA Issues New Policy to Help Expedite Availability of Diagnostics* (February 29, 2020), <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-new-policy-help-expedite-availability-diagnostics>.

²³ *Coronavirus Disease 2019 (COVID-19) Emergency Use Authorizations for Medical Devices*, FDA <https://www.fda.gov/medical-devices/emergency-use-authorizations-medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices> (last visited on Aug 10, 2020).

²⁴ *Id.*; See also *Public Readiness and Emergency Preparedness Act*, PHE, <https://www.phe.gov/Preparedness/legal/prepact/Pages/default.aspx> (last visited on Aug. 10, 2020).

²⁵ *Id.*

manufacturing industry.²⁶

The White House under President Trump also stumbled in invoking its authority created by the Defense Production Act (DPA).²⁷ The DPA was passed in 1950 at the start of the Korean War and was modeled after the War Powers Act that allowed President Roosevelt to control the domestic economy in wartime to make sure that the country had sufficient medical and military supplies.²⁸ Unlike the War Powers Act, wartime is not a required condition, and the DPA has been frequently used since its inception to fulfill government contracts for a variety of sectors, including defense.²⁹ For example, the DPA can be used to address and prepare for natural disasters and other cataclysmic events, even before such events occur.³⁰ Amongst many other things, the DPA enables the Office of the President to require private sector manufacturers to prioritize government orders and set production and distribution priorities for needed equipment.³¹ It also allows the President to order companies to recalibrate their factories to address shortages of supply.³² The Pentagon estimates that it invokes the DPA on at least 300,000 orders a year for various types of military equipment.³³ FEMA has frequently used it to address food and bottled water shortages following hurricanes.³⁴ However, 2020 was the first time it was used to address a public health emergency.³⁵

²⁶ “Section V: Covered Persons . . . manufacturer includes a contractor or subcontractor of a manufacturer; a supplier or licensor of any product, intellectual property, service, research tool or component or other article used in the design, development, clinical testing, investigation or manufacturing of a Covered Countermeasure; and any or all the parents, subsidiaries, affiliates, successors, and assigns of a manufacturer...” *Id.*

²⁷ Camila Domonoske, *White House Not Using Defense Powers To Boost Medical Supplies*, N.P.R. (Mar. 23, 2020), <https://www.npr.org/2020/03/23/820074051/white-house-not-using-defense-powers-to-boost-medical-supplies>; see also Maegen Vazquez, *Trump invokes Defense Production Act for Ventilator Equipment and N95 Masks*, CNN (Apr. 2, 2020), <https://www.cnn.com/2020/04/02/politics/defense-production-act-ventilator-supplies/index.html>.

²⁸ *Id.*

²⁹ *Id.*

³⁰ *Id.*

³¹ *Id.*

³² *Id.*

³³ Anshu Siripurapu, *What Is the Defense Production Act?* (Apr. 29, 2020), Council on Foreign Relations website available at <https://www.cfr.org/in-brief/what-defense-production-act>.

³⁴ *Id.*

³⁵ *Id.*

President Trump openly expressed hesitation in using the DPA, likening the U.S. to Venezuela should the U.S. choose to use the powers of the DPA to compel companies to produce PPE.³⁶ He eventually used the DPA on March 27, 2020 to require only six companies to ramp up production of patient monitors, CTs and mobile X-ray devices, hospital beds, face masks, oxygen blenders, resuscitation devices, and other respiratory medical equipment, many of which were already in the process of doing so.³⁷ In short, the federal government response was wholly inadequate.

C. Volunteer Efforts

Shortages continued long after the DPA was invoked. By March 25, 2020, a lack of access to PPE persisted nationwide in hospitals large and small.³⁸ This problem was only exacerbated in cash-strapped rural states suffering from shortages well into April 2020.³⁹

In response, volunteers stepped in to help with the manufacturing of medical supplies. Volunteer efforts manifested in sizeable numbers in unique ways, from individuals and companies making masks, to pilots helping with delivery and distribution.⁴⁰ For example, a family-owned manufacturer of car

³⁶ Ben Gittleson, *Defense Production Act Could Help Amid Coronavirus, Even as President Trump Resists: Experts* (Mar. 25, 2020), <https://preprod.abcnews.go.com/Politics/defense-production-act-amid-coronavirus-president-trump-resists/story?id=69789412>.

³⁷ Yelena Dzhanova, *Trump Compelled These Companies to Make Critical Supplies, but Most of Them Were Already Doing It*, CNBC (Apr. 4, 2020, 12:12 PM), <https://www.cnbc.com/2020/04/03/coronavirus-trump-used-defense-production-act-on-these-companies-so-far.html>.

³⁸ Rachel Chason, *Coronavirus Leads Hospitals, Volunteers to Crowdfund*, WASH. POST (Mar. 24, 2020), https://www.washingtonpost.com/local/social-issues/donate-ppe-hospitals-gloves-masks-doctors-nurses/2020/03/23/d781e4cc-6d00-11ea-aa80-c2470c6b2034_story.html.

³⁹ See, e.g., Anastasiya Bolton, *Rural Texas Hospitals 'Desperate' for Medical Supplies Needed to Fight Coronavirus* KHOU*11 (Apr. 6, 2020, 10:22 PM), <https://www.khou.com/article/news/health/coronavirus/rural-hospitals-desperate-for-coronavirus-medical-supplies/285-a8438a49-c178-43b0-95f5-1f3c4583be85>; Emily Paulin, *COVID-19 Deaths in Nursing Homes Plummet, Staff and PPE Shortages Persist*, AARP website (Mar. 11, 2021), <https://www.aarp.org/caregiving/health/info-2021/nursing-home-covid-deaths-down-shortages-continue.html>.

⁴⁰ Emma Platoff, *In West Texas, Volunteers Manufacture Medical Supplies and Amateur Pilots Deliver to Remote Hospitals*, THE TEXAS TRIBUNE (Apr. 20, 2020),

parts voluntarily re-configured their machinery to produce highly needed pistons.⁴¹ High-end New York City fashion designers felt the call to duty, and collaborated with the New York state government to produce between 500 to 1,000 face masks in a week; others committed to producing cloth face mask covers, lengthening the time a N95 respirator could safely be used.⁴² In Georgia, the Atlanta Opera entered an agreement with Grady Hospital to make cloth respirator covers.⁴³

The 3D printing community—i.e., those heavily engaged in the use of three-dimensional printers as either hobby or profession—also stepped up. Teachers and students at a private day school in Washington DC used 3D printers to produce face shields using open-sourced plans and by April, the students produced 3,000 face shields.⁴⁴ From Louisiana to Montana, 3D hobbyist families are creating production lines in their own homes using their 3D printers.⁴⁵ Similar stories abound in other cities such as Chicago,⁴⁶ and in some states, public universities are encouraging lay people to produce PPE for health care providers.⁴⁷

Nonprofits also began operating as quasi-distributors. Based out of New York City, Project N95 was formed before the President invoked the DPA, and was quickly able to serve as a switchboard for makers and health care

⁴¹ Kenny Malone & Karen Duffin, *Planet Money: The Parable Of The Piston*, N.P.R. (Apr. 2, 2020), <https://www.npr.org/2020/04/02/825800514/planet-money-the-parable-of-the-piston>.

⁴² Emilia Petrarca & Sarah Spellings, *Fashion Designers Are Pivoting to Face Masks*, N.Y. MAGAZINE (Mar. 23, 2020).

⁴³ Meredith Hobbs, *Troutman, Smith Gambrell Protect Volunteer PPE-Makers From Legal Liability*, LAW.COM (Apr. 7, 2020), <https://www.law.com/dailyreportonline/2020/04/07/troutman-smith-gambrell-protect-volunteer-ppe-makers-from-legal-liability/>.

⁴⁴ Ashraf Khalil, *DC's High School 'Makers' Fire Up 3D Printers to Create PPE*, NBC (Apr. 23, 2020), <https://www.nbcwashington.com/news/local/dcs-high-school-makers-fire-up-3d-printers-to-create-ppe/2282731/>.

⁴⁵ Devin Dwyer & Jacqueline Yoo, *Making 'PPE' at Home: Families Use 3D Printers to Address Coronavirus Shortages*, ABC NEWS (Apr. 9, 2020, 3:08 AM), <https://abcnews.go.com/Politics/making-ppe-home-families-3d-printers-address-coronavirus/story?id=69995774>.

⁴⁶ POLSKY CTR. FOR ENTREPRENEURSHIP & INNOVATION, *Maker Community Comes Together to 3D Print Personal Protective Equipment* (May 12, 2020), website available at <https://polsky.uchicago.edu/2020/05/12/maker-community-comes-together-to-3d-print-personal-protective-equipment/>.

⁴⁷ U. OF MARYLAND HEALTH SCIENCES & HUMAN SERVICES LIBR., *Making Personal Protective Equipment (PPE) for Health Care Workers: Home - Resources for Baltimore, Maryland and beyond during the Covid-19 pandemic* (Jul. 2, 2020), <https://guides.hshsl.umaryland.edu/ppe>.

providers in scores of cities all across the US.⁴⁸ These efforts spread nationally, such as #Findthemasks⁴⁹, and #getusppe (run by medical workers)⁵⁰, and in rural states as well,⁵¹ where rural hospitals already daunted by budget crises have been particularly vulnerable to cost increases of crucial PPE.⁵²

III. THE NEED FOR IP EXCEPTIONS DURING CRISIS

While the legal issues relating to crisis production are varied, this Article focuses on the issues relating to intellectual property, and though the discussion explores the burden on micro-manufacturers, the threat of liability extends also to distributors, distribution facilitators, and those who circulate patented plans and copyrighted ideas.⁵³ Consistent with this author's community economic development clinical practice, the discussion pays special attention to nonprofit organizations, small businesses, and individuals, or those netting little-to-no profit. However, much of the analysis is also applicable more widely to all companies outside the medical equipment industry with the capacity to produce PPE. For both categories of actors, the potential defendants are chilled from using their resources to do good given the various forms of liability incurred. I therefore advocate for laws that provide exceptions to IP infringement for purposes of crisis

⁴⁸ TJ McCue, *Project N95 Launches To Battle 2020 Shortage Of N95 Masks During Coronavirus Outbreak*, FORBES (Mar. 22, 2020), <https://www.forbes.com/sites/tjmccue/2020/03/22/project-n95-launches-to-battle-2020-shortage-of-n95-masks-during-coronavirus-outbreak/>.

⁴⁹ Find the Masks website available at <https://www.findthemasks.com/>.

⁵⁰ Get Us PPE website available at <https://getusppe.org/>.

⁵¹ Arkansas Regional Innovation Hub website available at <https://arhub.org/arkansas-maker-task-force/>.

⁵² Lauren Weber, *Coronavirus Threatens Rural Hospitals Already At The Financial Brink* KASU1-4 (Mar. 21, 2020, 5:00 A.M. CDT), <https://www.kasu.org/post/coronavirus-threatens-rural-hospitals-already-financial-brink#stream/0>.

⁵³ "Indirect infringement (i.e., inducement) may occur if an individual knowingly causes another person to 3D print a patented device. Indirect infringement (i.e., contributory infringement) may also occur if an individual knowingly sells an essential "component" of a patented device to another person who then 3D prints the device." Seila Mortazavi & Zaed M. Billah, *Are There Patent Infringement Implications of 3D Printing PPE to Help Health Care Workers in the War Against COVID-19? Yes.*, HUNTON ANDREWS KURTH 1, (Apr. 2, 2020), <https://www.huntonak.com/en/insights/are-there-patent-infringement-implications-of-3d-printing-ppe-to-help-health-care-workers-in-the-war-against-covid-19-yes-web.html>.

production.

A. *Intellectual Property As A Moral Right*

In his article, *Faith-Based Intellectual Property*, Mark Lemley first discusses the origins of intellectual property jurisprudence as one based on a utilitarian idea that intellectual property protections incentivize creativity.⁵⁴ He then documents the growing body of evidence reflecting that in fact, in most industries, intellectual property does not drive creativity, and in some cases hinders it.⁵⁵ Notably, evidence reflects that most patent litigation is brought against the creators themselves, rather than against copyists.⁵⁶

Even with this growing body of evidence, academics have continued to defend IP jurisprudence by arguing that “social utility alone is not reason enough to override [IP protections].”⁵⁷ Lemley derides this argument of intellectual property as a “moral right” in and of itself,⁵⁸ and likens it to an illogical, “faith-based” belief:

Because that is a belief, evidence cannot shake it any more than I can persuade someone who believes in the literal truth of the bible that his god didn’t create the world in seven days. Sure, there may be geological and archeological evidence that makes the seven-day story implausible. But faith is not just ambivalent about evidentiary support; it is remarkably resistant to evidentiary challenge...Now, you can think what you like about religion. I know lots of people who find value in it. But IP strikes me as an odd thing to make the basis of one’s faith...⁵⁹

⁵⁴ Mark Lemley, *Faith-Based Intellectual Property*, 62 UCLA L. REV. 1328 (2015), 1331, 1335.

⁵⁵ *Id.* at 1334, footnote 20. (Citing, amongst others, Teresa Amabile, CREATIVITY IN CONTEXT 33 (1996); Mihaly Csikszentmihalyi, CREATIVITY 107–08 (1996); Jeanne C. Fromer, *Expressive Incentives in Intellectual Property*, 98 VA. L. REV. 1745, 1777 (2012); Beth A. Hennessey & Teresa M. Amabile, *Reward, Intrinsic Motivation, and Creativity*, 53 AM PSYCHOLOGIST 674 (1998); William Hubbard, *Inventing Norms*, 44 Conn. L. Rev. 369 (2011); John Quiggin & Dan Hunter, *Money Ruins Everything*, 30 HASTINGS COMM. & ENT. L.J. 203, 214-15 (2008).

⁵⁶ Christopher A. Cotropia & Mark A. Lemley, *Copying in Patent Law*, 87 N.C. L. REV. 1421, 1423 (2009).

⁵⁷ Lemley, *supra* note 54 at 1337 (citing Merges, JUSTIFYING INTELLECTUAL PROPERTY 3 (2011)).

⁵⁸ *Id.* at 1336-37. (Discussing the work of Robert Berges at University of California at Berkeley, Richard Spinello and Maria Bottis, and multiple other intellectual property scholars.).

⁵⁹ *Id.* at 1338.

Indeed, the hesitation of much of the legal community to impinge on intellectual property rights is stalwart, even against the backdrop of public health emergencies. For example, tensions between global health and intellectual property have arisen in the past, during the anthrax scare after the 9/11 tragedy, and more recently, when a lab company brought a patent lawsuit against a COVID-19 testing firm.⁶⁰ Against this legal backdrop, well-meaning individuals and companies are trying to address an immediate PPE shortage for the public good; often on a volunteer, no-cost, or at-cost basis.

B. Patent Issues

In patent law, the potential for infringement by volunteers is rampant. While makers may be operating in good faith when they use plans and blueprints obtained from open-source websites, it is unlikely that volunteers operating in a crisis scenario have performed the extensive due diligence research needed to ensure that their design does not constitute patent infringement. A plan obtained from an open-source website can, in fact, infringe a patent. Liability could implicate not only the individual who proffered the design/invention as his or her own, but also the producer of the manufactured items; some might argue that liability could attach to the distributor or those who facilitate distribution. Without adequate clearance searching of the open-sourced plan against the USPTO's database of registered patents—which can cost hundreds or thousands of dollars and take weeks or months to complete thoroughly—there is no dispositive answer as to whether a use of plan or reproduction of an invention is an infringement of an existing patent.

Through the PREP Act of 2005, Congress created certain liability shields to facilitate production of PPE and related equipment, but not for the individuals, small businesses, and nonprofits from the aforementioned case studies.⁶¹ Rather, PREP protections were intended to protect large-scale professional manufacturers and end users (such as hospitals) in the industry

⁶⁰ Christopher Morten & Charles Duan, *The tension between public health and patents in the era of Covid-19*, STAT (Apr. 14, 2020), <https://www.statnews.com/2020/04/14/patents-public-health-tension-covid-19/>.

⁶¹ Families First Coronavirus Response Act, H.R. Res 6201, 116th Congress (2019-202). (Liability protection limited to § 6005. This section extends targeted liability protection to certain manufacturers, distributors, prescribers, and users of approved respiratory protective devices that are (1) subject to specified emergency use authorizations; and (2) used during the period beginning on January 27, 2020, and ending on October 1, 2024. Emergency use authorizations allow for the use of unapproved drugs, biological products, or devices, or for the unapproved use of such products, to respond to a declared emergency.

who already were undergoing an FDA approval process or complying with FDA regulations in many other related areas.⁶²

The PREP Act of 2005⁶³ provides immunity from liability for events arising from the “administration or use of countermeasures to diseases, threats and conditions determined by the Secretary to constitute a present, or credible risk of a future public health emergency to entities and individuals involved in the development, manufacture, testing, distribution, administration, and use of such countermeasures.”⁶⁴ It requires the Secretary of the Department of Health and Human Services to make a declaration specifically under the Act, which was made and incorporated into the CARES Act to address COVID-19.⁶⁵ The protection is limited to (1) “covered persons” (2) engaging in “recommended activities” (3) for “covered countermeasures.” A covered person is defined as a manufacturer of a countermeasure, a distributor, program planner of a countermeasure; a qualified person who prescribed, administered, or dispensed a countermeasure; or an official, agent or employee of a manufacturer, distributor, program planner or qualified person.⁶⁶ This language has been interpreted to mean those operating at a commercial level, such as a corporate manufacturer or common carrier,⁶⁷ and some have interpreted this liability protection to extend to intellectual property claims, such as patent infringement.⁶⁸

The extent to which our case study of volunteers are “covered persons” under the Act is unclear and underscores the inadequacy of the PREP Act in providing clear guidance to good Samaritan micro-manufacturers. Rather, the

⁶² *Id.*

⁶³ Joshua D. Sarnoff, *COVID-19 Highlights Need for Rights to Repair and Produce in Emergencies*, HARVARD LAW PETRIE FLOM CENTER (May 19, 2020), <https://blog.petrieflom.law.harvard.edu/2020/05/19/covid19-intellectual-property-patent-law/>.

⁶⁴ U.S. Dep’t of Health & Human Services, *Public Health Emergency*, available at <https://www.phe.gov/Preparedness/legal/prepact/Pages/default.aspx>.

⁶⁵ *Id.*

⁶⁶ U.S. Dep’t of Health and Human Services, *PREP Act Q&A’s, Immunity, 2. Who May be Afforded Immunity from Liability under a PREP Act Declaration?* available at <https://www.phe.gov/Preparedness/legal/prepact/Pages/prepqa.aspx#immune2>.

⁶⁷ U.S. Dep’t of Health and Human Services, *PREP Act Glossary of Terms* (“distributor”, and “manufacturer” available at <https://www.phe.gov/Preparedness/legal/prepact/Pages/prep-glossary.aspx#manufacturer>; Pillsbury Law *Covered Persons Table*, <https://www.pillsburylaw.com/images/content/1/3/130913/Covered-Person-Table.pdf>.

⁶⁸ See Morten, *supra* note 60.

PREP Act provides only after-the-fact relief that requires judicial interpretation of vaguely-defined protections for vaguely-defined parties.

1. Existing And Proposed Statutes Requiring Actions From The Federal Government

Either through legislation, or declarations issued by the White House or Congress, the federal government has an ability to offer relief to Good Samaritan PPE providers in a variety of ways.

- a. Facilitating innovation to fight coronavirus bill

The scenarios involving lay micro-manufacturers were likely contemplated and under discussion by Congress when they created the CARES Act, though nowhere in the Act is this issue addressed. The most noted feature of the CARES Act was the \$3 trillion package, a significant portion of which was dedicated to impacted businesses and unemployed individuals.⁶⁹ Some of this financial assistance included support to rural hospitals and for improvements to internet infrastructure in rural areas.⁷⁰ The CARES Act was passed unanimously by the Senate on March 25, 2020 and signed into law on March 27, 2020.⁷¹

Shortly thereafter, on April 13, 2020, Senator Bill Sasse of Nebraska introduced a bill to address the issues faced by Good Samaritan PPE producers called the “Facilitating Innovation to Fight Coronavirus Act” which has yet to be passed.⁷² The bill provides immunity for healthcare providers working outside their specialties or modifying FDA-approved devices for non-approved uses and conducting testing outside of certified healthcare facilities. In tandem with these allowances, it also proposes to suspend patent rights of inventions used to fight the coronavirus pandemic during the time period in which there is a National Emergency declaration by the President. As compensation to IP owners, the bill also proposes to extend the period of the invention’s patent for ten additional years, once the national emergency status is terminated.

As of the writing of this Article, the bill suffers from numerous fundamental shortcomings and faces much criticism. In its brevity (three pages), it fails to outline whether it would apply to existing patents or only those created during the period of coronavirus, and also does not adequately

⁶⁹ Pub.L. 116–136, H.R. 748.

⁷⁰ *Id.*

⁷¹ *Id.*

⁷² Facilitating Innovation to Fight Coronavirus Act, 116th Cong. S. 3 (March 30, 2020).

define its terms, specifically the definition of what is “used or intended for use in the treatment of...COVID-19.”⁷³ Others argue that the bill stifles innovation by disincentivizing costly experimentation removing the ability to recoup expenses until after the pandemic ends, at which time its inventions would no longer be in demand.⁷⁴ Other arguments decry that such loss of rights would result in the stripping from the patent-holder the ability to oversee quality control by the would-be infringer who could then produce dangerous or inferior products, or could price gouge.⁷⁵ Arguably, potential gouging could be prohibited by invoking certain provisions of the Defense Production Act.⁷⁶

Further, there is the question of proportionality; frequently, the patent-holder of an invention worthy of mass reproduction is a large, well-funded company and less often is it an individual inventor. Ostensibly, the state of emergency will subside with the introduction multiple vaccines that can be distributed widely and affordably. As of August 2021, 112 different vaccines are in clinical development, 183 in pre-clinical development,⁷⁷ and three are currently available for use in the United States.⁷⁸ As of December 2021, Baylor College of Medicine and Texas Children’s Hospital developed a version for distribution at low-cost in India.⁷⁹ However, as with many

⁷³ Courtenay C. Brinckerhoff, *Proposed Legislation To Delay, Then Extend Coronavirus Patents*, THE NAT’L L. REV. (Apr. 13, 2020), <https://www.natlawreview.com/article/proposed-legislation-to-delay-then-extend-coronavirus-patents>.

⁷⁴ James Edwards & Gene Quinn, *Facilitating Innovation to Fight Coronavirus Act— Legislation That’s a Mixed Bag*, IPWATCHDOG.COM, (Apr. 8, 2020), <https://www.ipwatchdog.com/2020/04/08/facilitating-innovation-to-fight-coronavirus-act-legislation-mixed-bag/id=120483/>.

⁷⁵ *Id.*

⁷⁶ Barren Avery, Brian Johnson & Orga Cadet, *Impact of the President’s Invocation of the Defense Production Act on Federal Contractors*, BAKER HOSTETLER, (Mar. 19, 2020), <https://www.bakerlaw.com/alerts/impact-of-the-presidents-invocation-of-the-defense-production-act-on-federal-contractors>.

⁷⁷ World Health Organization, *COVID-19 Vaccine Tracker*, available at, <https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines>.

⁷⁸ U.S. Food and Drug Administration, *COVID-19 Vaccines*, EMERGENCY PREPAREDNESS & RESPONSE: CORONAVIRUS DISEASE 2019 (COVID-19), <https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines>.

⁷⁹ Texas Children’s Hospital and Baylor College of Medicine COVID-19 Vaccine Technology Secures Emergency Use Authorization in India, available at, <https://www.texaschildrens.org/texas-children%E2%80%99s-hospital-and-baylor-college-medicine-covid-19-vaccine-technology-secures-emergency>.

diseases—vaccines, PPE, and other COVID-19-related treatment items will have marketability long after a pandemic.

b. Compulsory licenses and the TRIPS agreement

Various nations around the world have proposed the establishment of compulsory licenses in the context of the inventions needed to combat COVID-19. In a compulsory license, one is authorized to copy, make, use or sell the intellectual property without the permission of the owner.⁸⁰ A compulsory license could establish a fixed licensing fee for the use or reproduction of a qualifying patented (or copyrighted) creation, and such license would be mandatory. Costa Rica, Chile, Colombia, Peru, Malaysia, the Netherlands and Israel are amongst the cohort of nations that either have already adopted compulsory licensing for inventions related to the virus, or are taking such a policy under consideration.⁸¹

Under the Trade-Related Intellectual Property Agreement (TRIPS Agreement), signed by all members of the World Trade Organization including the United States, federal governments of member nations can create compulsory licenses and utilize a patented work from any member nation without the authorization of the patent-holder.⁸² It is a threshold agreement in which member nations can provide more but not less protection for the individual patent-holder. It creates exceptions to patent protection so long as the patent-holder is not unreasonably affected or prevented from exploiting the patent herself, and explicitly creates the right to establish compulsory licensing.⁸³ Most European countries have opted into a compulsory licensing policy of some sort,⁸⁴ and under a 2006 EU agreement, most EU countries must allow for compulsory licensing to the least developed and developing countries.⁸⁵ Even under these agreements,

⁸⁰ Glossary, World Trade Organization, https://www.wto.org/english/thewto_e/glossary_e/glossary_e.htm

⁸¹ Elaine Ruth Fletcher & Svět Lustig Vijay, *Costa Rica Urges WHO To Lead Global Initiative For Pooled Rights To COVID-19 Diagnostics, Drugs & Vaccines*, HEALTH POLICY WATCH (Mar. 3, 2020), <https://www.healthpolicy-watch.org/costa-rica-urges-who-to-lead-global-initiative-for-pooled-rights-to-covid-19-diagnostics-drugs-vaccines/>.

⁸² TRIPS Agreement, https://www.wto.org/english/docs_e/legal_e/31bis_trips_02_e.htm.

⁸³ *Id.*

⁸⁴ European Patent Academy, *Compulsory licensing in Europe A country-by-country overview*, EUROPEAN PATENT OFFICE (2018), [http://documents.epo.org/projects/babylon/eponot.nsf/0/8509F913B768D063C1258382004FC677/\\$File/compulsory_licensing_in_europe_en.pdf](http://documents.epo.org/projects/babylon/eponot.nsf/0/8509F913B768D063C1258382004FC677/$File/compulsory_licensing_in_europe_en.pdf).

⁸⁵ Council Regulation 816/2006, 2006 O.J. (L. 157) 1, 7 (EC).

however, a country must first try to obtain permission of the patent-holder, except for in extreme circumstances such as a pandemic. The compulsory license may only last for the duration of the emergency, and the amount of the licensing fee is open to litigation. Compulsory licensing is also available in copyright, which does not require emergency circumstances and may be in place indefinitely.⁸⁶

In the U.S., compulsory licensing is most commonly used in non-dramatic music; musicians may cover the original composition of another for a fixed statutory fee per reproduction.⁸⁷ So long as the melody of the original composition is preserved, the copyright holder may not object or litigate the amount.⁸⁸ Also in the US, compulsory licensing is also used in public broadcasting,⁸⁹ retransmission by cable systems,⁹⁰ subscription digital audio transmission,⁹¹ and non-subscription digital audio transmission such as internet radio.⁹²

In patent law, however, the U.S. has not enacted laws to enable compulsory licensing in the same fashion as has Europe.⁹³ U.S. compulsory licensing of patents exist for plant variety protection to secure fiber, food, and feed supply;⁹⁴ all patents for use by the U.S. government itself;⁹⁵ or where the U.S. has funded the research and development at least in part.⁹⁶ The latter authority, termed “march-in” rights, has never been used and is more thoroughly discussed in the next section.

Recently, President Joe Biden made a historic move in expressing support to waive coronavirus vaccine patents.⁹⁷ In doing so, he surprised

⁸⁶ WIPO Guide on the Licensing of Copyright and Related Rights, World Intellectual Property Organization, 2004. p. 101. ISBN 978-92-805-1271-7.

⁸⁷ See generally 17 U.S.C. § 115.

⁸⁸ Coe Ramsey & Brooke Pierce, *Music Law 101: Common Music Licenses*, JDSupra, (July 17, 2019), <https://www.jdsupra.com/legalnews/music-law-101-common-music-licenses-81898/>.

⁸⁹ 17 U.S.C. 118.

⁹⁰ 17 U.S.C. 111(c).

⁹¹ 17 U.S.C. 114(d)(2).

⁹² 17 U.S.C. 114(d)(1).

⁹³ Nafsika Karavida & Dara Onofrio & Deena Merlen, *Patent Rights and Wrongs in the COVID-19 Pandemic: EU and U.S. Approaches to Compulsory Licensing*, IPWATCHDOG (May 19, 2020), <https://www.ipwatchdog.com/2020/05/19/patent-rights-wrongs-covid-19-pandemic-eu-u-s-approaches-compulsory-licensing/id=121709/>.

⁹⁴ 7 U.S.C. § 2404 (2000).

⁹⁵ See generally 28 U.S.C. § 1498.

⁹⁶ 35 U.S.C. § 203.

⁹⁷ Amy Maxmen, *In shock move, U.S. backs waiving patents on COVID vaccines*, NATURE: NEWS (May 6, 2021), <https://www.nature.com/articles/d41586->

congressmembers from both sides of the political spectrum, “mark[ing] a shift in policy in a major, pro-public health way,” according to health law scholar Matthew Kavanaugh of Georgetown University.⁹⁸ However, even with the best of intentions by President Biden, a patent waiver under the TRIPS Agreement would not be triggered until all members of the World Trade Organization agree to a waiver and related terms.⁹⁹ And, even should all nations agree to a patent waiver (and indications exist that not all EU nations would do so), this would only comprise step one of a three step process, the latter of which are incredibly time and resource intensive.¹⁰⁰ The second and third steps, knowledge transference followed by large scale investment in manufacturing infrastructure, are equally necessary¹⁰¹ and may not occur quickly enough to effectively address the ever-mystifying coronavirus and its quickly growing number of variants.

Prior to President Biden’s expression of public support of a coronavirus vaccine patent waiver, there is just one other documented case of potential patent waiving, in which Tommy Thompson, the Secretary of the Department of Health and Human Services threatened to “break” the patent for Cipro, held by German-based company Bayer, in order to stockpile supplies to treat anthrax during a 2001 nationwide scare.¹⁰² The legal structure through which Secretary Thompson intended to use is unclear, given that Bayer backed down before litigation occurred and sold the needed supplies at the government’s requested price. Generally, however, the U.S. has held firm on its position of upholding patent rights in the pharmaceutical industry, even when concerning life-saving drugs needed to treat HIV/AIDS or malaria in multiple countries in Africa,¹⁰³ and it is unclear whether President Biden’s support in waiving a vaccine patent will be meaningful should even one member of the World Trade Organization hold oppose.

The U.S. (and Western World’s) predilection against compulsory licensing in medical supplies not only prejudices good Samaritans diligently seeking to address supply shortages, but also greatly prejudices the U.S. as

021-01224-3#author-0.

⁹⁸ *Id.*

⁹⁹ *Id.*

¹⁰⁰ *Id.*

¹⁰¹ “‘It’s a one-two-three,’ explains Rachel Cohen, U.S. director for the non-profit Drugs and Neglected Diseases initiative in New York City. ‘First we need to remove patent obstacles, second we need to transfer the knowledge on how to make them, and step three is a massive investment in manufacturing capacity,’ ” *Id.*

¹⁰² Jill Carroll & Ron Winslow, *Bayer to Slash by Nearly Half Price U.S. Pays for Anthrax Drug*, WALL ST. J. (Oct. 25, 2001), <https://www.wsj.com/articles/SB1003966074330899280>.

¹⁰³ *Id.*

successful vaccines are developed elsewhere, if the production of multiple vaccines is required to vaccinate the entire U.S. population, as well as those needing to enter the US, as quickly as possible. Many argue that the assumption that compulsory licenses only grossly prejudices investors is a false one,¹⁰⁴ and that pro-market economic justifications for compulsory licenses do in fact exist.¹⁰⁵ However, the scope of this Article primarily focuses on non-pharmaceutical inventions and will not further address the arguments for and against compulsory licensing in the pharmaceutical context.

Rather, a distinction could be made in the inventions discussed in the case study (ventilator parts, and PPE such as masks, gowns, respirators) and high costs items such as pharmaceuticals. We might look to the distinction between granting compulsory licenses in copyright versus pharmaceutical patents; that difference may be driven by the disparity in cost of research and development for a drug greatly exceeding the costs needed to develop a song, for instance. Thus, it may be that the government is more willing to require compulsory licensing in one context over the other. However, given the broad spectrum of medical equipment in which there are shortages, perhaps the U.S. might consider revisiting this legal tool as applied to equipment with lower research and development costs, and leave the rarely used march-in rights device as the measure for items with higher start-up costs.

c. March-in rights under the Bayh-Doyle Act

The Bayh-Dole Act is considered one of the most definitive pieces of legislation in the U.S. patent and innovation law. Its centerpiece features 1) enabled inventors of federally funded inventions to maintain ownership of intellectual property rights for purposes of commercialization, and 2) enabled the government to grant exclusive licenses to any intellectual property it owns. As part of a balancing feature of this pro-market legislation, the Bayh-Dole Act also reserved for the federal government certain march-in rights,¹⁰⁶ allowing the federal government to override the intellectual property rights of the patent holder under certain circumstances, including any time it deems it “necessary to alleviate health or safety needs.”¹⁰⁷ This enables the

¹⁰⁴ Jerome H. Reichman, *Compulsory licensing of patented pharmaceutical inventions: evaluating the options*, J LAW MED ETHICS (2009 Summer) 37(2): 247–263, <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2893582/>

¹⁰⁵ Sean Flynn, Aidan Hollis & Mike Palmedo, *An Economic Justification for Open Access to Essential Medicine Patents in Developing Countries*, J. OF L. MEDICINE & ETHICS (2009), <https://pubmed.ncbi.nlm.nih.gov/19493066/>.

¹⁰⁶ 35 U.S. C. § 203(a) (2021).

¹⁰⁷ *Id.*

government to manufacture the invention itself, or direct a private sector company to do so; in return, certain types of patent holders (e.g., nonprofits or individuals) may sue the government for “reasonable and entire compensation for such use and manufacture”, including the cost of litigation to collect such.¹⁰⁸ Past precedent indicates that reasonable royalties would include at least 10% of sales, and a compensation plan that could include the cost of development adjusted for risk and other factors.¹⁰⁹ The legislative intent appears to contemplate situations in which the patent-holder fails to move forward on a patent against the public’s best interests.

The drawbacks from this approach are two-fold: 1) the protection is limited only to those patents in which the research and development was funded by a federal agency; and 2) this requires a proactive government that has the wherewithal not only to confront the private sector but also to undertake production and commercialization. Given how previous presidential administrations have been hesitant in using their clear-cut authority under the DPA to compel the private sector into manufacturing sufficient PPE other than for a handful of necessary pieces of medical equipment, it is unwise to rely exclusively on the wisdom of the office of the President to engage its power to use its march-in rights. It is worthy to note that the Trump administration was not alone in its hesitation; never before in the history of the U.S. have march-in rights been used.

2. Non-Government Solutions: Solutions Requiring Legal Expertise, High Costs & Sufficient Time

Others have pointed to potential solutions that require actions by either the patent holders, the would-be patent infringers, or both. These potential solutions do not rely on federal or state governments to compel action from private patent-holders or confer liability protection through a statute.

a. Due diligence procedures

Some practitioners have recommended that good Samaritan PPE producers adopt a three-part process before engaging in the potentially infringing activity. The process includes 1) obtaining an IP clearance, 2) researching the IP asserted, and 3) requiring requesting party to supply all

¹⁰⁸ 28 U.S.C. § 1498(a) (2021).

¹⁰⁹ Michael Liu, William Feldman, Jerry Avorn & Aaron Kesselheim, *March-In Rights And Compulsory Licensing—Safety Nets For Access To A COVID-19 Vaccine*, HEALTH AFFAIRS BLOG (May 6, 2020), <https://www.healthaffairs.org/doi/10.1377/hblog20200501.798711/full/>.

info it possesses about relevant IP and infringement risks.¹¹⁰

b. Creative licensing and patent pooling

These same practice experts have also suggested a contractual method to avoid patent infringement. For instance, they suggest that the Good Samaritan PPE producer negotiate a creative licensing arrangement with the patent-holder allowing him to produce a limited supply under defined circumstances for a minimal fee.¹¹¹ Others have suggested negotiating for a patent pooling arrangement, in which a set of patent holders issue a pooled license that results in licensing fees that become more affordable for the Good Samaritan PPE producers as an economy of scale is reached.¹¹²

c. Contractual devices

Practitioners have also suggested relying on legal language in agreements and notifications. For instance, the Good Samaritan PPE producer could draft indemnification language in a supply contract when asked to produce PPE.¹¹³ She should also insert statements making clear that no representations or warranties of intellectual property ownership is being made by reproduction of such items.¹¹⁴ The good Samaritan PPE producers could also require the requesting party to purchase insurance against IP infringement or obtain it on its own.

All of the devices described in this section, however, require the time and expertise of a patent attorney, (and the recognition for the need for one first and foremost) which the Good Samaritan PPE producers in the case study will not likely be able to afford. Even if the financial resources were present, the time needed to negotiate a sophisticated pooled patent arrangement or to

¹¹⁰ John Cotter, Patrick McElhinny, Christopher Verdini & Christopher Warner, *COVID-19: IP Strategies for Universities and Nonprofits During the Pandemic – Mitigating Patent Infringement Risks When Making PPE and Other Health-Related Supplies*, NAT'L L. REV (Apr. 23, 2020).

¹¹¹ Michael Horikawa, *As a Response to COVID-19, 3D Printing Provides Some Wins ... and Some Compelling Intellectual Property Questions*, JDSUPRA (Mar. 25, 2020), <https://www.jdsupra.com/legalnews/as-a-response-to-covid-19-3d-printing-52289/>.

¹¹² Michael Horikawa, *As a Response to COVID-19, 3D Printing Provides Some Wins ... and Some Compelling Intellectual Property Questions*, JDSUPRA (Mar. 25, 2020), <https://www.jdsupra.com/legalnews/as-a-response-to-covid-19-3d-printing-52289/>.

¹¹³ *Id.*

¹¹⁴ *Id.*

undergo a due diligence process can be extremely time intensive and unrealistic in a pandemic environment.

3. Potential New, Common Law Doctrines As Relief

Given the inertia of the federal government to use its authority, and the level of legal sophistication and resources required of good Samaritan PPE producers to adopt due diligence review or negotiated solutions, perhaps the more realistic option would be the development of protective legal doctrines.

a. Right to repair and produce extended to pandemic

The right to repair and produce doctrine enables purchasers of inventions to repair the physical property purchased, using un-patented parts, and without requiring the permission of the patent-holder. This “exhaustion doctrine”, has been upheld by the U.S. Supreme Court.¹¹⁵ However, case law left open the possibility that liability might still exist in the case of patented medical devices, (e.g., ventilator parts); nor has the Court addressed the possibility that such parts are not available in sufficient supply during a life-threatening pandemic, or might only be available at exorbitant prices. While this may not cover the full spectrum of PPE, a revised version of this doctrine certainly could be relevant to the reproduction of ventilator parts, and other components of critical machinery.

b. March-in rights by proxy

The current conditions suggest a need for a doctrine which allows others to engage in roles traditionally filled by the government to address shortages of PPE and other critical supplies. These are issues often characterized as ones of national security and there is clear, statutory, Congressional authorization for the government, specifically, the President and federal agencies on his behalf, to act. The fact that the President and the President’s administrative directors choose not to do so does not take away the identified need and the administrative authority to do so.

Where government agencies and the President fail to act or, for whatever reason, are unable to act in a way that sufficiently addresses these national security issues, the courts should explore the concept of march-in-rights by proxy to protect, and even incentivize organizations and individual actors to act in a way that serves the public. These entities, whether they are nonprofit

¹¹⁵ *Impression Prods., Inc. v. Lexmark Int’l, Inc.*, 137 S. Ct. 1523, 1529 (2017).

organizations, individuals, or for-profit businesses should be allowed to undertake at least some of the activities authorized by the Bayh-Dole Act as part of the march-in rights on patents that were developed with federal funding. Specifically, these actors should be authorized a license to use the patent where there is a finding that the patent-holder has not exploited these rights in a manner that threatens national security. The patent-holder should be paid a reasonable amount for exploitation that includes reimbursement of research and development, and possibly ten percent of any proceeds after production costs of the infringer are covered, just as they would be entitled to had the federal government been the one to execute its march-in rights. In essence, the relief given to the patent-holder would mirror any relief possible under the Bayh-Dole march-in rights, and the good Samaritan infringers would be able to act without being punished for their good deeds.

The creation of march-in rights by proxy dovetails off of the concept that third parties should be able to utilize intellectual property where there is a necessity, and where the IP owner has not sufficiently commercialized the invention on a scale needed to address an emergent public need. March-in rights by proxy would not disincentivize inventions because the patent holders would still recover a portion of fees and reimbursement for research and development if such profits are made, and this would only occur where such R&D expenses were at least partially funded by the federal government.

c. DPA by proxy

Should the courts adopt a doctrine of march-in rights by proxy, a gap in protection remains where the would-be infringer exploits a patent that did not in fact receive funding from a federal agency. For those instances, the doctrine of DPA by Proxy could be a viable solution. Under this theory, a third party could break the patent and compel a compulsory license under the same circumstances outlined in the DPA for the government: the would-be infringer must make a due diligent effort to contact the patent-holder except in extreme circumstances such as a pandemic; the license may only last for the duration of the emergency, the would-be infringer cannot interfere with the patent-holder's use and commercialization of the patent, and the amount licensing fee can include a percentage of profits and reimbursement of R&D costs if the would-be infringer sells for an amount in excess of production costs. The would-be infringers would be required to comply with all other relevant aspects of the DPA such as the prohibition against hoarding and gouging.¹¹⁶

¹¹⁶ "...to prevent hoarding, no person shall accumulate (1) in excess of the reasonable demands of business, personal, or home consumption, or (2) for the purpose of resale at prices in excess of prevailing market prices." 50 U.S.C. § 4512.

Under DPA by Proxy, a balance between the interests of the patent-holder and the good Samaritan would-be infringer are met: the good Samaritan is not penalized for acting on behalf of an immediate public interest unmet by the government or the patent-holder, and the patent-holder is compensated for her expenses if there is any money to be made.

C. Copyright

In addition to patent, the need for free use of copyrighted materials is exacerbated during the pandemic.¹¹⁷ This section will consider the potential for infringement of copyrighted works by those who must adapt to functioning in a time of crisis.

Consider some of the copyrighted items pledged as free IP during COVID-19, such as manuals, blueprints, datasets, and technical drawings. More specifically, some of the items pledged include an “[i]nstruction manual to construct a low cost, easy-to-use outdoor shelter for healthcare workers to conduct safer COVID-19 drive-up or walk-up testing;”¹¹⁸ a technical drawing for a “Safe Supply” outdoor grocery store set up by Bow Market Somerville to provide a COVID-19 friendly layout, with a suggested operational structure using pre-scheduled time slots and one-way paths; a touchless ordering system¹¹⁹; and a “dataset of anonymized Bing queries relating to the COVID pandemic, useful for research on the spread and containment of the pandemic, public concerns and the information being disseminated about it” pledged by Microsoft.¹²⁰

Beyond the response to the pandemic itself, the free use of copyrighted materials is likewise important in an educational environment radically altered by COVID-19. Libraries have had to close with faculty, staff and students coming to rely on virtual materials and modes of instruction. Professors have had multiple students who were displaced in the early weeks of the pandemic and who had to be sent digital copies of course texts with the physical copies now thousands of miles away. As classes have moved online,

¹¹⁷ See, e.g., Matthew Bultman, *Online Teaching During Pandemic Raises Copyright Concerns*, *Bloomberg Law*, BLOOMBERG LAW (Apr. 3, 2020), <https://news.bloomberglaw.com/ip-law/online-teaching-amid-virus-raises-copyright-questions>.

¹¹⁸ *Sandia-Drive Up Booth for Safer COVID-19 Testing*, OPEN COVID PLEDGE, (May 20, 2020), <https://opencovidpledge.org/2020/05/20/drive-up-booth-for-safer-covid-19-testing/>.

¹¹⁹ *Bow Market-Grocery Design*, OPEN COVID PLEDGE (May 20, 2020), <https://opencovidpledge.org/2020/05/20/bow-market/>.

¹²⁰ *Microsoft – Covid-19 Search Data*, OPEN COVID PLADGE (May, 29, 2020), <https://opencovidpledge.org/2020/05/19/microsoft-bing/>.

teachers tend to record students as a matter of policy, capturing copyrighted audiovisual material recordings—e.g., YouTube videos, music, photographs—along with the lectures.¹²¹

1. Flexible Licenses

Certain authors and publishers have extended permissions in the form of “flexible licenses” to utilize materials.¹²² In terms of textbooks, some publishers, like Cengage and Cambridge University Press, have allowed college students free access to digital copies of textbooks. And Macmillan Children’s Publishing Group and HarperCollins Children’s Books, as well as author J.K. Rowling, have allowed teachers to post videos of themselves reading their books to children. While such permission is helpful in isolated instances, a clarification that emergency uses of copyrighted materials constitute fair use during a pandemic would provide responders, educators, and students with confidence that they are not breaking the law in adapting to radically altered demands. Perhaps copyright’s fair use doctrine could be helpful in that regard.

2. Fair use

The common law-derived doctrine of fair use is currently copyright’s only safety valve. In 1976, it was codified in the Copyright Act.¹²³ Fair use consists of four factors to consider in determining whether use of a copyrighted work is “fair” and thus not constituting copyright infringement. These factors are: (1) the purpose and character of the use; (2) the nature of the copyrighted work; (3) the amount and substantiality of the portion used in relation to the copyrighted work as a whole; and (4) the effect of the use upon the potential market for or value of the copyrighted work.¹²⁴ Overall, fair use is intended to serve as a flexible mechanism designed to balance the interests of copyright holders with the interests of other creators and the public.¹²⁵

¹²¹ Emily Hudson & Paul Wragg, *Proposals for Copyright Law and Education During the Covid-19 Pandemic* (June 3, 2020) (unpublished manuscript available at <file:///C:/Users/dmarlan/Downloads/SSRN-id3617720.pdf>).

¹²² Matthew Bultman, *Online Teaching During Pandemic Raises Copyright Concerns*, BLOOMBERG LAW (Apr. 3, 2020), <https://news.bloomberglaw.com/ip-law/online-teaching-amid-virus-raises-copyright-questions>.

¹²³ 37 C.F.R. 201.2(a)(3).

¹²⁴ *Id.*

¹²⁵ Kara Yorio, *A Crisis-as in School Closures Due to Coronavirus-Justifies Fair*

On March 13, 2020, a group of copyright specialists—college, university, and public librarians—released a public statement regarding “Fair Use & Emergency Remote Teaching & Research.”¹²⁶ The Statement is “meant to provide clarity for U.S. colleges and universities about how copyright law applies to the many facets of remote teaching and research in the wake of the COVID-19 outbreak.”¹²⁷ In evaluating the fair use factors, the Statement concludes that although no fair use decisions “squarely address[es] copying to help minimize a public health crisis, the other variety of public benefits cited by courts leads us to believe that this purpose would weigh extremely heavily in favor of fair use.”¹²⁸

The Statement then goes on to analyze the copying during a public health emergency under the four fair use factors. What follows is a summary of that analysis interspersed with our own thoughts on how fair use might apply.

Under the first factor—“the purpose and character of the use”—courts tend to “favor uses where the purpose is to benefit the public, even when that benefit is not ‘direct or tangible.’”¹²⁹ This factor, considered “the heart of the fair use inquiry,” tends to consider whether the use is “transformative in nature.” Here, while the copyrighted works themselves may be substantially the same as the original version, the circumstance itself—a once in a century pandemic—can be found to be highly transformative.

As to the second factor—“the nature of the copyrighted work”—it is rarely considered in a fair use analysis.¹³⁰ However, in certain cases, works that provide a “substantial public benefit” lean toward a holding of fair use.¹³¹ This would certainly seem applicable to works used in adapting during times of crisis.

Use, Say Librarians, SLJ (Mar. 14, 2020), <https://www.slj.com/?detailStory=librarians-address-copyright-concerns-argue-fair-use-applies-amid-academic-closures-coronavirus-covid19>.

¹²⁶ *Public Statement of Library Copyright Panelists: Fair Use & Remote Teaching & Research* (Mar. 13, 2020), <https://docs.google.com/document/d/10baTITJbFRh7D6dHVvfgiGP2zqaMvm0EHHZYf2cBRk/mobilebasic#ftnt6>, (citing *Authors Guild v. Google, Inc.*, 804 F.3d 202 (2d Cir. 2015); *Time Inc. v. Bernard Geis Assocs.*, 293 F. Supp. 130 (S.D.N.Y. 1968); *Online Policy Grp. v. Diebold, Inc.*, 337 F. Supp. 2d 1195 (N.D. Cal. 2004).

¹²⁷ *Id.*

¹²⁸ *Id.*

¹²⁹ *Id.*, citing *Sega Enterprises Ltd. v. Accolade, Inc.*, 977 F.2d 1510, 1523 (9th Cir. 1992), as amended (Jan. 6, 1993).

¹³⁰ *Id.*. See Paris Convention at art. 5A; G.H.C. Bodenhausen, *Guide to the Application of the Paris Convention for the Protection of Industrial Property, as Revised at Stockholm in 1968*, 1968, at 71, 80.

¹³¹ See, e.g., *A.V. ex rel. Vanderhye v. iParadigms*, 562 F.3d 630 (4th Cir. 2009) (holding that a digital antiplagiarism service “provide[d] a substantial public benefit.

The third factor—“the amount and substantiality of the work”—encourages reasonableness. “A use can be fair,” according to the Statement, “as long as it reproduces what is reasonable to serve the purpose.” Copying the entirety of a work, or at least a substantial portion of it, in the educational context during COVID-19 appears to be reasonableness given the circumstances, in many cases.¹³²

The fourth and final factor is “the effect of the use upon the potential market for the copyright work.”¹³³ It “requires a balancing of the benefit the public will derive if the use is permitted” as compared to “the personal gain the copyright owner will receive if the use is denied.”¹³⁴ According to the Statement:

While in normal circumstances there may be licensing markets for some items, the spontaneity of a move to remote teaching under emergency circumstances reduces the importance of this factor. Checking for and relying on licensed alternatives bolsters the case for fair use under the fourth factor, but lack of time to check for licenses should not be a barrier to meeting the needs of our communities.¹³⁵

The problem with fair use, though, is that, as Michael Carroll notes, its “context sensitivity renders it of little value to those who require reasonable ex ante certainty about the legal value of a proposed use.”¹³⁶ We do not know if something, in other words, is a fair use prior to a legal determination, which only occurs once a legal proceeding is well under way. A law that declares emergency use of copyright materials in the context of a pandemic, analogous to the common law doctrines discussed in the next Part, would therefore be preferable to relying on individual fair use determinations in preventing the chilling of productive uses of copyrighted as well as patented materials. Thus, solutions beyond fair use appear to be warranted.

¹³² See, e.g., *Authors Guild v. Google Inc.*, 770 F. Supp. 2d 666 (2d Cir. 2015) (“unchanged copying has repeatedly been found justified as fair use when the copying was reasonably appropriate to achieve the copier’s transformative purpose and was done in such a manner that it did not offer a competing substitute for the original”); *Kelly v. Arriba Soft Corp.*, 336 F.3d 811 (9th Cir. 2003).

¹³³ *Id.*

¹³⁴ *Id.*

¹³⁵ *Public Statement of Library Copyright Panelists: Fair Use & Remote Teaching & Research* (Mar. 13, 2020), <https://docs.google.com/document/d/10baTITJbFRh7D6dHVvVfGiGP2zqaMvm0EHHZYf2cBRk/mobilebasic#ftnt6>.

¹³⁶ Michael W. Carroll, *Fixing Fair Use*, 85 N. CAR. L. REV. 1087 (2007).

*D. Common Law Analogies For Proposed Legislation Permitting
Emergency Uses*

This subpart analogizes the common law in proposing a statutory emergency exemption to certain intellectual property liabilities in the face of the Covid-19 pandemic. In doing so, it looks to (1) Good Samaritan laws, (2) the public necessity defense to trespass, and (3) landlord-tenant law, in the context of eviction moratoriums during COVID-19. In each of these cases, emergencies provide defenses to violations of tort or property rights. In the case of IP's statutory regimes, though, no exemptions to infringement, either for patent or copyright, exist for crises despite incredible need.

The constitutional purpose of intellectual property—at least as to patent and copyright—is “to promote the Progress of Science and the useful Arts.”¹³⁷ Guiding the Constitution's Intellectual Property clause is the longstanding premise that economic incentives are needed to encourage inventors and creators.¹³⁸ This proposal does not appeal to a moral claim, which is long out of favor in the utilitarian world of intellectual property. Instead, each of the following analogies is intended to show that during times of crisis, IP's *individual* economic incentives must sometimes yield to incentivize *collective* public interests. To the extent that IP can be likened to tangible property, these common law doctrines can be used as guidance in fashioning an emergency declaration regarding intellectual property liability in the wake of COVID-19.

1. Good Samaritan Laws

Good Samaritan laws—those protecting anyone who renders aid in an emergency to one who is sick or injured—provide the first area of analogy. Good Samaritan doctrines in the U.S. have long provided a defense against tort claims (most often negligence) arising from attempted rescue.¹³⁹ Though originally derived from the common law, Good Samaritan laws have, since

¹³⁷ U.S. Const. Art. I, § 8, cl. 8.

¹³⁸ Cf. Eric E. Johnson, *Intellectual Property and the Incentives Fallacy*, 39 Fl. State L. Rev 623, 624-79 (2012) (criticizing the incentives justification given that social science finds that “innovative and creative activity will thrive without artificial support.”); Shyamkrishna Balganesh, *Foreseeability and Copyright Incentives*, 122 HARV. L. REV. 1572-1633 (2008) (“Copyright's principal justification has for long been the theory of creator incentives . . . Yet current copyright doctrine does surprisingly little to give effect to this theory.”).

¹³⁹ Brian West & Matthew Varacallo, *Good Samaritan Laws*, (Sept. 20, 2020) <https://www.ncbi.nlm.nih.gov/books/NBK542176/>.

1959, been codified in statute in all 50 states.¹⁴⁰ Their elements generally include some minor variation of: (1) the care was performed as a result of an emergency; (2) the initial emergency was not caused by the volunteer; and (3) the emergency care was not given by the volunteer in a grossly negligent or reckless manner.¹⁴¹ For example, Massachusetts' Good Samaritan Law reads:

Any person, whose usual and regular duties do not include the provision of emergency medical care, and who, in good faith, attempts to render emergency care including, but not limited to, cardiopulmonary resuscitation or defibrillation, and does so without compensation, shall not be liable for acts or omissions, other than gross negligence or willful or wanton misconduct, resulting from the attempt to render such emergency care.¹⁴²

Some statutes go further in mandating a duty to rescue, to the extent that a bystander witnesses an emergency, he or she must, in these states, such as Rhode Island, assist those who are suffering, thus requiring assistance to be rendered during a true medical emergency.¹⁴³ In April of 2020, the Wisconsin state government implemented rules providing immunity from civil liabilities resulting from injuries related to the manufacture and distribution of "emergency medical equipment" for "disease associated with the public health emergency related to the novel coronavirus pandemic."¹⁴⁴ The immunity is limited to "Good Samaritan" suppliers where the items are either donated, or sold "at a price not to exceed the cost of production."¹⁴⁵

The purpose of a Good Samaritan law, as a matter of public policy, is to encourage emergency assistance by removing the threat of liability for damage done by the assistance.¹⁴⁶ It is meant to protect those that do not

¹⁴⁰ *Id.*

¹⁴¹ *Id.*

¹⁴² G. L. c.258C, § 13.

¹⁴³ *See West, supra* note 139.

¹⁴⁴ Paul J. Covalski & Josh Johanningmeier, *Wisconsin COVID-19 Law Includes Limited Civil Liability Immunities for Suppliers of Essential Equipment and Medical Professionals*, NAT'L L. REV, XI 270, (Apr. 15, 2020).

¹⁴⁵ *Id.*

¹⁴⁶ Brian West & Matthew Varacallo, *Good Samaritan Laws*, (Sept. 20, 2020) (unpublished manuscript available at <https://www.ncbi.nlm.nih.gov/books/NBK542176/>) (also noting that "the premise underlying the good Samaritan law traces its origin to the ancient biblical definition of a good Samaritan as an individual who intervenes to assist another individual without prior notion or responsibility or Samaritan *promise of compensation.*"); Eric A. Brandt, *Good Laws – The Legal Placebo: A Current Analysis*, 17 AKRON LAW REVIEW (1984) (noting the biblical origin).

usually administer assistance—i.e., non-experts—in the event they encounter an individual who needs help. In other words, if people stopped to think about whether they will face liability prior to offering potentially life-saving assistance, valuable time would be lost. Thus, “we are improved as a society if the potential rescuers (i.e., the good Samaritans) are solely concerned about helping a person in need as opposed to worrying about the possible liability associated with assisting their fellow man or woman.”

2. Public Necessity

In tort law, the common law doctrine of necessity is an affirmative defense that can be used against charges of trespass to real or personal property—an intentional tort—in cases where a defendant interferes with a plaintiff’s property out of need. Trespass is an infringement on a property owner’s legal right to enjoy the benefits of ownership, in which a civil action can be brought. The law draws a distinction between private necessity—where the trespass is necessary to protect harm to oneself or others—and public necessity—an emergency situation to protect the greater community or society as a whole from a greater harm that would have occurred had the defendant not committed trespass. While private necessity provides only a partial defense to trespass, public necessity serves as an absolute defense where a defendant is not liable for any damages caused by trespass.

The action of public necessity consists in appropriating or destroying another’s property so as to avert a public calamity.¹⁴⁷ According to the Restatement Second of Torts: “One is privileged to enter land in the possession of another if it is, or if the actor reasonably believes it to be, necessary for the purpose of averting an imminent public disaster.”¹⁴⁸ The classic case involves destroying property to prevent the spread of disease or fire or other calamity and thus injury to the public.¹⁴⁹ The elements of necessity are the following: (1) a reasonable belief that one’s actions were necessary to prevent imminent harm; (2) there was no practical alternative available for avoiding the harm; (3) the actor did not cause the threat of harm in the first place; and (4) the damage caused was less than the harm that would

¹⁴⁷ Perhaps the landmark case of public necessity is *Surocco v. Geary*, 3 Cal. 69 (Cal. 1853) (mayor of San Francisco ordered fire department to destroy plaintiff’s house to contain wildfires; defense successful because potential damage to the city would have been substantially more severe without the order to demolish the plaintiff’s home.).

¹⁴⁸ Restatement (Second) of Torts § 196 (Am. L. Inst. 1965).

¹⁴⁹ The paradigmatic cases of private necessity include *Vincent v. Lake Erie Transportation Co.*, 124 N.W. 221 (Minn. 1910) (destruction of wharf to save life) and *Ploof v. Putnam*, 71 A. 188 (Vt. 1908) (destruction of dock to save life)

have occurred otherwise. The principle underlying public necessity is that the law regards the welfare of the public as superior to individual interests. Thus, individual interests must yield to collective ones when there is a conflict between the two.¹⁵⁰

According to renowned criminal law scholar Glanville Williams, “Some acts that would otherwise be wrong are rendered rightful by a good purpose, or by the necessity of choosing the lesser of two evils.”¹⁵¹ Like the Good Samaritan doctrine, public necessity can be seen as a utilitarian calculation consistent with modern IP theory, not a moral principle. That is, courts grant necessity privileges when the risk of harm to an individual (in the case of private necessity) or the public (in the case of public necessity) is greater than the harm to property. In situations “where there is an unhappy choice between the destruction of one life and the destruction of many, utilitarian philosophy would certainly justify the actor in preferring the lesser evil.”¹⁵² Indeed, necessity “represents a concession to human weakness in cases of extreme pressure, where the accused breaks the law rather than submitting to the probability of greater harm if he does not break the law.” In this way, public necessity is consistent with the economic and utilitarian calculus underlying modern patent and copyright law.¹⁵³

In a pandemic area, we may need to appropriate the intellectual property of others to save lives. To the extent we consider intellectual property the functional equivalent of real or personal property, trespassing on a patent or copyright would be excused and no damages should be awarded if the reason was COVID-19 related. This is because when a private actor invokes public necessity, they have a complete privilege and do not have to pay compensation to the property owner.¹⁵⁴

3. Emergency Bans on Evictions During COVID-19

In the real property context, many states, counties, and municipalities across the country are taking disparate steps to minimize the impact of COVID-19 on tenants by putting moratoriums on evictions, prohibiting late

¹⁵⁰ John Alan Cohan, *Private and Publicity Necessity and the Violation of Property Rights*, 83 N. DAKOTA L. REV. 651, 653 (2007) (citing *City of Durham v. Eno Cotton Mills*, 54 S.E. 453, 464 (1906)).

¹⁵¹ Glanville Williams, *The Sanctity of Life and the Criminal Law* (Alfred. A Knopf. Inc. 1957).

¹⁵² *Id.* at 200.

¹⁵³ *But see* George C. Christie, *The Defense of Necessity Considered from the Legal and Moral Points of View*, 48 DUKE L. J. 975 (1999).

¹⁵⁴ RESTATEMENT (SECOND) OF TORTS § 196 cmt. a (AM. LAW. INST. 1965).

rent fees and putting holds on the shut off of utilities due to nonpayment.¹⁵⁵ Landlords are ordinarily allowed to evict tenants under circumstances where rent is past due, assuming certain conditions are met—but not so during COVID. Under the CARES Act, renters living in properties with government-backed mortgages were being protected from eviction, at least temporarily.¹⁵⁶ Freddie and Fannie Mae have so far prohibited landlords of single-family properties with Freddie and Fannie Mae backed mortgages from evicting tenants.¹⁵⁷

If copyright and patent are forms of property, then copyright and patent owners can be considered a sort of landlord. This argument is based on a certain rhetorical move. As Brian L. Frye argues in his essay, *Literary Landlords in Plaguetime*, to the extent that copyright owners argue that copyright is a property right, roughly analogous to real and tangible property rights, then copyright owners naturally function as landlords.¹⁵⁸ Landlords own real property and rent it to others. This is how they generate revenue.

Frye writes regarding the analogy to copyright owners:

[C]opyright owners own copyrights in order to generate a profit by renting works of authorship to consumers. You don't need to own the copyright in a work of authorship in order to consume it, you just need the permission of the copyright owner. Copyright has economic value only because it enables copyright owners to generate revenue by renting works of authorship to people who want to consume them. If no one rents a work of authorship, then it isn't generating any revenue. Copyright owners are analogous to landlords because they own a (potentially) valuable capital asset and generate revenue by collecting rents from its consumption. Indeed, the analogy is delightfully apt because the congruence is so obvious, once observed.

Property is, as philosopher Samir Chopra notes, “the foundation of a culture and the foundation of an economic system.”¹⁵⁹ From both political

¹⁵⁵ Ann O’Connell, *Emergency Bans on Evictions and Other Tenant Protections Related to Coronavirus*, NOLO, (Sept. 24, 2021) <https://www.nolo.com/legal-encyclopedia/emergency-bans-on-evictions-and-other-tenant-protections-related-to-coronavirus.html>.

¹⁵⁶ *Id.*

¹⁵⁷ *Id.*

¹⁵⁸ Frye, *supra* note 7, at 238.

¹⁵⁹ Samir Chopra, *End Intellectual Property*, AEON (Nov. 12, 2018), <https://aeon.co/essays/the-idea-of-intellectual-property-is-nonsensical-and-pernicious> [<https://perma.cc/75VE-84EC>]; See also Richard M. Stallman, *Did You Say ‘Intellectual Property’? It’s a Seductive Mirage*, 4 POL’Y FUTURES EDUC. 334 (2006) (arguing that we should stop using the term intellectual property); Cf. JAMES BOYLE, *The Public Domain: Enclosing The Commons Of The Mind* 8 (2008) (noting that the concerns with the term “intellectual property” are “real and

and economic perspectives, property has “expressive impact,” “ideological weight and propaganda value.”¹⁶⁰ Put differently, the property metaphor serves to moralize intellectual property law, despite its more common U.S. claim of being utilitarian—based on economic incentives.¹⁶¹ To suggest that property is involved implies that IP “can be stolen, and therefore must be protected with the same zeal that the homeowner guards her home against invaders and thieves.”¹⁶² But not always. As Frye puts it, “[i]f you live by the [property] metaphor, you die by the metaphor.”¹⁶³

Under this analogy, where copyright is a form of rent-seeking, and by natural extension patent, what is needed in times of crisis is a moratorium on copyright and patent damages similar to the 2020 moratorium on real property rents.

IV. CONCLUSION

This Article has highlighted the need for emergency relief from intellectual property liability—or the threat of liability—during the COVID-19 pandemic. In the context of patent and copyright, I have discussed the potential for liability, focusing especially on the PPE crisis, against the backdrop of increasingly strengthened intellectual property protections and the moral right perspective. I offer a balanced approach, focusing on existing potential solutions including march-in rights, compulsory licensing, and free IP pledges, and also potential new solutions based in well-recognized doctrines and concepts in property law. I conclude that ultimately, an emergency protection declaration along these lines of argument could provide a comprehensive solution so that collective efforts aimed at combating the pandemic are appropriately balanced with patent and copyright’s individual economic incentives model during this time of crisis.

* * *

well-founded” but disagreeing with the conclusion that we should give up the term considering its usefulness as an umbrella category); Dustin Marlan, *Is the Word Consumer Biasing Trademark Law*, 8 Tex. A&M L. Rev. 367, 372 (2021) (arguing that “the term property obscures the realization that beyond the party that “owns” the intellectual property right, there is an excluded public domain whose interests are not being rhetorically accounted for by use of the term.”).

¹⁶⁰ *Id.*

¹⁶¹ Frye, *supra* note 7, at 236.

¹⁶² Chopra, *supra* note 159.

¹⁶³ Frye, *supra* note 7, at 244.